RU2276996C2 - Лечение повреждений головного мозга, спинного мозга и нервов - Google Patents

Лечение повреждений головного мозга, спинного мозга и нервов Download PDF

Info

Publication number
RU2276996C2
RU2276996C2 RU2002121640/15A RU2002121640A RU2276996C2 RU 2276996 C2 RU2276996 C2 RU 2276996C2 RU 2002121640/15 A RU2002121640/15 A RU 2002121640/15A RU 2002121640 A RU2002121640 A RU 2002121640A RU 2276996 C2 RU2276996 C2 RU 2276996C2
Authority
RU
Russia
Prior art keywords
substance
receptor antagonist
brain
damage
composition according
Prior art date
Application number
RU2002121640/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2002121640A (ru
Inventor
Роберт ВИНК (AU)
Роберт ВИНК
Алан Джон НИММОУ (AU)
Алан Джон НИММОУ
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2002121640A publication Critical patent/RU2002121640A/ru
Application granted granted Critical
Publication of RU2276996C2 publication Critical patent/RU2276996C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RU2002121640/15A 2000-01-18 2001-01-18 Лечение повреждений головного мозга, спинного мозга и нервов RU2276996C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ5146A AUPQ514600A0 (en) 2000-01-18 2000-01-18 Brain injury treatment
AUPQ5146 2000-01-18

Publications (2)

Publication Number Publication Date
RU2002121640A RU2002121640A (ru) 2004-03-27
RU2276996C2 true RU2276996C2 (ru) 2006-05-27

Family

ID=3819274

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002121640/15A RU2276996C2 (ru) 2000-01-18 2001-01-18 Лечение повреждений головного мозга, спинного мозга и нервов

Country Status (20)

Country Link
US (5) US6841551B2 (OSRAM)
EP (1) EP1261335B1 (OSRAM)
JP (1) JP4794794B2 (OSRAM)
KR (1) KR100780119B1 (OSRAM)
CN (1) CN1261095C (OSRAM)
AU (2) AUPQ514600A0 (OSRAM)
BR (1) BR0107695A (OSRAM)
CA (1) CA2397723C (OSRAM)
CZ (1) CZ20022804A3 (OSRAM)
DE (1) DE60139244D1 (OSRAM)
HR (1) HRP20020593B1 (OSRAM)
HU (1) HUP0301920A3 (OSRAM)
IL (2) IL150548A0 (OSRAM)
MX (1) MXPA02007004A (OSRAM)
NO (1) NO329320B1 (OSRAM)
NZ (2) NZ519990A (OSRAM)
RU (1) RU2276996C2 (OSRAM)
WO (1) WO2001052844A1 (OSRAM)
YU (1) YU54702A (OSRAM)
ZA (1) ZA200205715B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749191C2 (ru) * 2011-03-14 2021-06-07 Н.В. Нютрисиа Способ лечения нейротравмы

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
DE602004028678D1 (de) 2003-01-28 2010-09-23 Ironwood Pharmaceuticals Inc Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
WO2006110118A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit cytoprotecteur
US20060239921A1 (en) 2005-04-26 2006-10-26 Novadaq Technologies Inc. Real time vascular imaging during solid organ transplant
WO2006116634A2 (en) 2005-04-26 2006-11-02 Novadaq Technologies, Inc. Method and apparatus for vasculature visualization with applications in neurosurgery and neurology
US10231624B2 (en) * 2005-08-10 2019-03-19 Nov Adaq Technologies Ulc Intra-operative head and neck nerve mapping
US20070122344A1 (en) * 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
US8945623B2 (en) * 2006-05-03 2015-02-03 Warsaw Orthopedic, Inc. Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
US20080161744A1 (en) * 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
US20080241121A1 (en) * 2007-04-02 2008-10-02 Daniela Salvemini Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain
US20100086543A1 (en) * 2007-04-02 2010-04-08 Saint Louis University Compositions and methods for treating conditions associated with ceramide biosynthesis
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100184819A1 (en) * 2007-07-19 2010-07-22 Robert Vink Method for reducing intracranial pressure
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
US20090263507A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
EP3372250B1 (en) 2008-05-02 2019-12-25 Novadaq Technologies ULC Methods for production and use of substance-loaded erythrocytes for observation and treatment of microvascular hemodynamics
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
NO2384318T3 (OSRAM) 2008-12-31 2018-04-14
US8852566B2 (en) * 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012074043A1 (ja) * 2010-12-03 2012-06-07 国立大学法人 岡山大学 外傷性神経障害治療剤
EP2863801B8 (en) 2012-06-21 2024-06-12 Stryker Corporation Quantification and analysis of angiography and perfusion
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP3552630A1 (en) 2013-04-12 2019-10-16 Ardelyx, Inc. Nhe3-binding compounds for inhibiting phosphate transport
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
US10729677B2 (en) * 2013-07-02 2020-08-04 Eustralis Pharmaceutical Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-I
EP3016659A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iii
US20160129007A1 (en) * 2013-07-02 2016-05-12 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV
RU2674653C2 (ru) * 2013-07-02 2018-12-12 Юстрэлиз Фармасьютикалз Лимитед (Трейдинг Эз Пресшура Нейро) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
US9816930B2 (en) 2014-09-29 2017-11-14 Novadaq Technologies Inc. Imaging a target fluorophore in a biological material in the presence of autofluorescence
CA2963450A1 (en) 2014-10-09 2016-04-14 Novadaq Technologies Inc. Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
BR112019013963A2 (pt) 2017-01-09 2020-04-28 Ardelyx Inc inibidores de antiporte mediado por nhe
US11242337B2 (en) 2017-01-09 2022-02-08 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
EP4242743A3 (en) 2017-02-10 2023-10-18 Stryker European Operations Limited Open-field handheld fluorescence imaging systems and methods
WO2021035289A1 (en) * 2019-08-23 2021-03-04 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic methods and uses thereof
WO2021202286A1 (en) * 2020-03-30 2021-10-07 Dignify Therapeutics, Llc Compositions and methods for treating autonomic dysreflexia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2055078C1 (ru) * 1989-12-22 1996-02-27 Фудзисава Фармасьютикал Ко., Лтд. Производные дипептидов и способ их получения
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
US5716979A (en) * 1992-08-13 1998-02-10 Warner-Lambert Company Tachykinin antagonists
WO1999064009A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist for treating cognitive disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481139A (en) * 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4985896A (en) * 1985-03-29 1991-01-15 Canon Kabushiki Kaisha Laser driving device
US4981744A (en) * 1990-04-24 1991-01-01 Swank Michael W Non-planar expandable honeycomb structure
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
AU5265596A (en) * 1996-04-12 1997-11-07 Neotech Medical Innovations, Inc. Composition and method for the treatment of premenstrual syndrome
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
JP2001513562A (ja) * 1997-08-28 2001-09-04 メルク エンド カムパニー インコーポレーテッド 月経前または黄体後期症候群の治療方法
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
RU2238264C2 (ru) 1999-02-24 2004-10-20 Ф.Хоффманн-Ля Рош Аг Производные бензола или пиридина и фармацевтическая композиция на их основе
JP4068305B2 (ja) 1999-02-24 2008-03-26 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニルピリジン誘導体、およびそのｎｋ−１受容体拮抗薬としての用途
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6479433B1 (en) * 2000-10-02 2002-11-12 Smithers-Oasis Company Polyurethane foam composites for grower applications and related methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2055078C1 (ru) * 1989-12-22 1996-02-27 Фудзисава Фармасьютикал Ко., Лтд. Производные дипептидов и способ их получения
US5716979A (en) * 1992-08-13 1998-02-10 Warner-Lambert Company Tachykinin antagonists
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
WO1999064009A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist for treating cognitive disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Руководство по медицине. THE MERCK MANUAL. - M.: Мир, 1997, т.1, c.991. Реферат из АБД Medline: Heald D.L. Vink R. Magnesium sulphate improves neurologic outcome following severe closed head injury in rats.Neurosci. Lett. 1997, Jun. 13; 228(3):175-8. Реферат из АБД Medline: Heald D.L., Vink R. Optimization of magnesium therapy after severe diffuse axonal brain injury in rats. J. Pharmacol. Exp. Ther. 1999, Mar; 288(3):1311-6. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749191C2 (ru) * 2011-03-14 2021-06-07 Н.В. Нютрисиа Способ лечения нейротравмы

Also Published As

Publication number Publication date
HRP20020593A2 (en) 2005-10-31
ZA200205715B (en) 2003-10-17
EP1261335A1 (en) 2002-12-04
EP1261335A4 (en) 2004-09-22
NO20023423D0 (no) 2002-07-17
KR100780119B1 (ko) 2007-11-27
HK1054872A1 (en) 2003-12-19
RU2002121640A (ru) 2004-03-27
US20050107380A1 (en) 2005-05-19
IL150548A (en) 2011-05-31
EP1261335B1 (en) 2009-07-15
NZ519990A (en) 2004-10-29
CZ20022804A3 (cs) 2002-11-13
US20030109417A1 (en) 2003-06-12
AU2656001A (en) 2001-07-31
NO20023423L (no) 2002-09-16
US20160030474A1 (en) 2016-02-04
US10201568B2 (en) 2019-02-12
YU54702A (sh) 2006-01-16
DE60139244D1 (de) 2009-08-27
WO2001052844A1 (en) 2001-07-26
AU782799B2 (en) 2005-09-01
CA2397723C (en) 2010-08-31
JP2003520232A (ja) 2003-07-02
MXPA02007004A (es) 2004-10-15
HUP0301920A2 (hu) 2003-09-29
IL150548A0 (en) 2003-02-12
NO329320B1 (no) 2010-09-27
BR0107695A (pt) 2002-10-15
HRP20020593B1 (hr) 2011-03-31
HUP0301920A3 (en) 2010-03-29
AUPQ514600A0 (en) 2000-02-10
US6841551B2 (en) 2005-01-11
CN1261095C (zh) 2006-06-28
US9186404B2 (en) 2015-11-17
PL358251A1 (en) 2004-08-09
NZ534278A (en) 2005-08-26
CN1426302A (zh) 2003-06-25
CA2397723A1 (en) 2001-07-26
JP4794794B2 (ja) 2011-10-19
US20180071333A1 (en) 2018-03-15
US20090253698A1 (en) 2009-10-08
KR20020075784A (ko) 2002-10-05

Similar Documents

Publication Publication Date Title
RU2276996C2 (ru) Лечение повреждений головного мозга, спинного мозга и нервов
RU2244558C2 (ru) Анестетическая композиция, включающая антагонист nmda и альфа-2 адренергический агонист
Pazzaglia et al. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation
Klamt et al. Postoperative analgesic effect of intrathecal neostigmine and its influence on spinal anaesthesia
Johansson et al. A double-blind controlled study of a serotonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients
JP2010504926A (ja) 痛みの治療のための混合されたＯＲＬ１／μ−アゴニスト
Fenten et al. Systemic local anesthetic toxicity after local infiltration analgesia following a polyethylene tibial insert exchange: a case report
KR20020068404A (ko) 미르타자핀을 포함하는, 우울증 및 관련 장애 치료용 약물조합물
KR20040025882A (ko) 신경성 통증 치료 및 예방약
US6436937B1 (en) Use of desoxypeganine in the treatment of Alzheimer's dementia
JPH02502920A (ja) てんかんの発作の治療用製薬組成物
AU2008225378A1 (en) Novel preventive and/or therapeutic agent for neuropathic pain
DE60305018T2 (de) Citalopram zur behandlung von bluthochdruck
RU2112558C1 (ru) Способ внутривенного общего обезболивания
HK1054872B (en) Brain, spinal and nerve injury treatment
PL203468B1 (pl) Preparat do do zylnego lub domi esniowego leczenia uszkodzenia mózgu, rdzenia kr egowego i nerwów
MX2007012517A (es) Composicion farmaceutica sinergistica de carisoprodol y clonixinato de lisina.
Kadian et al. INTRAINCISIONAL VS INTRAPERITONEAL INFILTRATION OF LOCAL ANAESTHETIC FOR CONTROLLING POST-LAPAROSCOPIC CHOLECYSTECTOMY PAIN

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120119